Transcatheter Edge-to-Edge Repair for Tricuspid Regurgitation: Design and Rationale of the TEER-CHINA Trial.

Authors

Kaida Ren, Boren Tan, Xinping Lin, Zhaoxia Pu, Lihan Wang, Po Hu, Jubo Jiang, QiFeng Zhu, Jiaqi Fan, Yuxin He, Yuchao Guo, Qiong Liu, Jie Liang, Huajun Li, Huixiang Yan, Haochang Hu, Xianbao Liu, Jian'an Wang

Published in

JACC. Asia. Jul 20, 2026. Epub Jul 20, 2026.

Abstract

Tricuspid regurgitation (TR) is common, and severe TR independently predicts mortality and heart failure hospitalization, leading to functional impairment and poor quality of life. Optimal medical therapy (OMT), mainly using diuretic agents, provides symptomatic relief but does not correct valvular dysfunction and is often limited by the resistance of diuretic agents. Isolated tricuspid valve surgery remains high risk. Transcatheter options have therefore emerged, with transcatheter edge-to-edge repair (TEER) widely adopted.
The Transcatheter Edge-to-Edge Repair for Tricuspid Regurgitation in China (TEER-CHINA) study is designed to evaluate the safety and efficacy of the DragonFly-T System compared with OMT in patients with severe TR.
The TEER-CHINA trial is a prospective, multicenter, randomized controlled trial (NCT05556460) in which a total of 236 participants will be enrolled across 35 centers in China and randomized 1:1 to the device group or OMT alone. Key inclusion criteria include patients with severe or greater TR (≥3+) who remain clinically symptomatic despite OMT for at least 30 days, are at intermediate or higher surgical risk for tricuspid valve surgery by the local Heart Team, and are anatomically suitable for use of the investigational device. Participants will be followed up at 30 days, 6 months, 12 months, and annually thereafter for up to 5 years.
The primary endpoint is a hierarchical composite assessed at 12 months, including all-cause mortality or tricuspid valve intervention, annualized heart failure hospitalization rates, and improvement in health status measured by the Kansas City Cardiomyopathy Questionnaire.
The TEER-CHINA trial is designed to assess the efficacy and safety of the DragonFly-T System and to inform future treatment strategies for severe TR.

PMID:
42496618
Bibliographic data and abstract were imported from PubMed on 24 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.